Bruce Culleton, MD, is the newly appointed CEO of ProKidney Corp., having taken over the role on November 15, 2023. He brings over 20 years of experience in kidney health from both industry and academia. Before stepping into the CEO...

Bruce Culleton, MD, is the newly appointed CEO of ProKidney Corp., having taken over the role on November 15, 2023. He brings over 20 years of experience in kidney health from both industry and academia. Before stepping into the CEO position, Dr. Culleton was the Executive Vice President of Clinical Development and Commercialization at ProKidney. He's also held significant roles at CVS Kidney Care and Becton, Dickinson and Company, where he made key contributions to their kidney-focused advancements. His educational background is solid—a Bachelor's degree in Medical Science, a Doctor of Medicine, and an MBA from Northwestern University's Kellogg School of Management. As CEO, he earns a base salary of $625,000 with performance bonuses that aim to align with corporate achievements. Outside his professional life, Dr. Culleton is known for his commitment to improving kidney care, which is a key mission of ProKidney Corp.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other ProKidney Corp. CEOs

P

Bruce Culleton, MD

CEO of ProKidney Corp.

Education

Bachelor's degree in Medical Science and a Doctor of Medicine degree from Memorial University of Newfoundland; MBA from Northwestern University, Kellogg School of Management.

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1967 - 58 years ago

CEO of ProKidney Corp. for

1 year 8 months (Nov 2023 - Present)

Previous Experience

Vice President and General Manager of CVS Kidney Care, LLC; Vice President and Chief Medical Officer at CVS Kidney Care; Vice President, Global Clinical Development at Becton, Dickinson and Company; Vice President, Renal Therapeutic Area at Baxter International Inc.

Rivals

Competitors/colleagues of Bruce Culleton, MD

Holdings

See how much did Bruce Culleton, MD make over time.

Dr. Culleton recently received options to purchase 3,000,000 shares of ProKidney Corp. at an exercise price of $1.69 following his appointment as CEO. These options align with his long-term commitment to the company's success. His previous role as Executive Vice...

Dr. Culleton recently received options to purchase 3,000,000 shares of ProKidney Corp. at an exercise price of $1.69 following his appointment as CEO. These options align with his long-term commitment to the company's success. His previous role as Executive Vice President, Clinical Development and Commercialization positioned him well when he succeeded Tim Bertram as CEO. The vesting schedule for his shares spans over several years which ties his financial success to the performance of ProKidney. While he has currently no vested stock or substantial stock holdings reported, his substantial options package indicates a strong potential for wealth accumulation linked directly to the company’s success. Excitingly, he could see a significant financial reward as the company's strategies unfold in the growing kidney health sector.

Loading...

Insider Trading

See recent insider trades of Bruce Culleton, MD.

No insider trades found for this CEO.

Compensation History

See how much did Bruce Culleton, MD make over time.

In 2023, Dr. Culleton's total compensation reached $8.7 million, but this figure mainly includes stock options rather than cash. His base salary stands at $625,000, with a significant opportunity for bonuses — 60% of his salary — based on the company's performance. Despite having a cash bonus of around $120,824 for the year, he didn't receive any stock grants or options that actually vested. Instead, his compensation mix reflects a focus on long-term incentives which can grow significantly based on ProKidney's performance in the kidney health market, a sector rapidly gaining attention as therapeutic advancements increase. His compensation package is designed to attract and retain leaders with the vision to drive the company's mission and strategy.

Year

2023

Total Compensation

$366.68K

Salary

$244.96K

Board Justification

The compensation program is designed to attract, retain, and motivate senior management leaders capable of advancing the company's mission and strategy, rewarding them in alignment with financial performance and equity ownership.

Bonus

$120.82K

Board Justification

Cash bonuses earned by the named executive officers pursuant to our Non-Equity Incentive Compensation Plan for performance, with a corporate goal achievement of 59.8%.

Other

$891.00

Board Justification

Represents all other compensation paid to Dr. Culleton including insurance premiums with respect to a group life insurance policy, a group short-term disability policy, a group long-term disability policy, an accidental death and dismemberment policy, and flexible spending accounts.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as per the provided data.

Performance Metrics

Performance metrics for the CEO's compensation in 2023 were based on corporate goal achievements.

Other ProKidney Corp. CEOs

Here are other CEOs of ProKidney Corp.

Tim Bertram, Ph.D.

Ex-CEO of ProKidney Corp.

June 2021 - November 2023